Cargando…

Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System

PURPOSE: The purpose of this first in-human study was to evaluate the overall clinical performance of the VERITAS™ Vision System in patients scheduled to undergo cataract extraction and to confirm overall surgeon acceptability. PATIENTS AND METHODS: This prospective, open-label multinational study i...

Descripción completa

Detalles Bibliográficos
Autores principales: Quesada, Gabriel, Chang, Daniel H, Waltz, Kevin L, Kao, Andrew A, Quesada, Rodrigo, Wang, Ying, Ji, Leilei, Parizadeh, Dari, Atiles, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365053/
https://www.ncbi.nlm.nih.gov/pubmed/35968054
http://dx.doi.org/10.2147/OPTH.S363061
_version_ 1784765265750261760
author Quesada, Gabriel
Chang, Daniel H
Waltz, Kevin L
Kao, Andrew A
Quesada, Rodrigo
Wang, Ying
Ji, Leilei
Parizadeh, Dari
Atiles, Luis
author_facet Quesada, Gabriel
Chang, Daniel H
Waltz, Kevin L
Kao, Andrew A
Quesada, Rodrigo
Wang, Ying
Ji, Leilei
Parizadeh, Dari
Atiles, Luis
author_sort Quesada, Gabriel
collection PubMed
description PURPOSE: The purpose of this first in-human study was to evaluate the overall clinical performance of the VERITAS™ Vision System in patients scheduled to undergo cataract extraction and to confirm overall surgeon acceptability. PATIENTS AND METHODS: This prospective, open-label multinational study included adults with cataracts scheduled for planned cataract extraction and posterior chamber IOL implantation. Standard small-incision phacoemulsification cataract surgery with the VERITAS Vision System was conducted. Surgeons completed a questionnaire regarding their clinical experience with the VERITAS Vision System for each patient following surgery and 1-day postoperative. Corneal clarity and adverse events (AEs) were assessed. Surgeon acceptability was scored on a 5-point scale, with acceptability considered favorable for scores of 4 and 5. RESULTS: A total of 115 eyes (79 patients) were treated. The El Salvador site treated 41 patients (58 eyes), and the US site treated 38 patients (57 eyes). Overall, surgeons were satisfied with the clinical performance regardless of the cataract grade. The satisfaction with anterior chamber stability, post-occlusion surge, followability, holdability, cutting efficiency, usability, and overall satisfaction with the VERITAS Vision System was clinically favorable in ≥99% of cases. Overall satisfaction with the swivel handpiece, foot pedal, and enhanced ergonomics were clinically favorable in ≥97% of cases regardless of the cataract grade. Satisfaction with corneal clarity at same-day postoperative and 1-day postoperative, and 1-day overall clinical results of surgery with the VERITAS Vision System were clinically favorable in ≥94% of cases regardless of cataract grade. CONCLUSION: The new dual-mode phacoemulsification system with dual-durometer tubing, gas forced infusion, new swivel handpiece, and ergonomics improvements resulted in a high rate of user satisfaction with clinical performance and ergonomics. The VERITAS Vision System is safe and effective when used as indicated.
format Online
Article
Text
id pubmed-9365053
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93650532022-08-11 Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System Quesada, Gabriel Chang, Daniel H Waltz, Kevin L Kao, Andrew A Quesada, Rodrigo Wang, Ying Ji, Leilei Parizadeh, Dari Atiles, Luis Clin Ophthalmol Clinical Trial Report PURPOSE: The purpose of this first in-human study was to evaluate the overall clinical performance of the VERITAS™ Vision System in patients scheduled to undergo cataract extraction and to confirm overall surgeon acceptability. PATIENTS AND METHODS: This prospective, open-label multinational study included adults with cataracts scheduled for planned cataract extraction and posterior chamber IOL implantation. Standard small-incision phacoemulsification cataract surgery with the VERITAS Vision System was conducted. Surgeons completed a questionnaire regarding their clinical experience with the VERITAS Vision System for each patient following surgery and 1-day postoperative. Corneal clarity and adverse events (AEs) were assessed. Surgeon acceptability was scored on a 5-point scale, with acceptability considered favorable for scores of 4 and 5. RESULTS: A total of 115 eyes (79 patients) were treated. The El Salvador site treated 41 patients (58 eyes), and the US site treated 38 patients (57 eyes). Overall, surgeons were satisfied with the clinical performance regardless of the cataract grade. The satisfaction with anterior chamber stability, post-occlusion surge, followability, holdability, cutting efficiency, usability, and overall satisfaction with the VERITAS Vision System was clinically favorable in ≥99% of cases. Overall satisfaction with the swivel handpiece, foot pedal, and enhanced ergonomics were clinically favorable in ≥97% of cases regardless of the cataract grade. Satisfaction with corneal clarity at same-day postoperative and 1-day postoperative, and 1-day overall clinical results of surgery with the VERITAS Vision System were clinically favorable in ≥94% of cases regardless of cataract grade. CONCLUSION: The new dual-mode phacoemulsification system with dual-durometer tubing, gas forced infusion, new swivel handpiece, and ergonomics improvements resulted in a high rate of user satisfaction with clinical performance and ergonomics. The VERITAS Vision System is safe and effective when used as indicated. Dove 2022-08-06 /pmc/articles/PMC9365053/ /pubmed/35968054 http://dx.doi.org/10.2147/OPTH.S363061 Text en © 2022 Quesada et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Quesada, Gabriel
Chang, Daniel H
Waltz, Kevin L
Kao, Andrew A
Quesada, Rodrigo
Wang, Ying
Ji, Leilei
Parizadeh, Dari
Atiles, Luis
Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title_full Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title_fullStr Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title_full_unstemmed Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title_short Clinical Performance and Surgeon Acceptability of a New Dual Mode Phacoemulsification System
title_sort clinical performance and surgeon acceptability of a new dual mode phacoemulsification system
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365053/
https://www.ncbi.nlm.nih.gov/pubmed/35968054
http://dx.doi.org/10.2147/OPTH.S363061
work_keys_str_mv AT quesadagabriel clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT changdanielh clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT waltzkevinl clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT kaoandrewa clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT quesadarodrigo clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT wangying clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT jileilei clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT parizadehdari clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem
AT atilesluis clinicalperformanceandsurgeonacceptabilityofanewdualmodephacoemulsificationsystem